Good to see some other small players with cancer treatments are being given BTD:
Up until now, the FDA has reserved its new "breakthrough" designation for a Who's Who in drug development, with high-profile companies like J&J, Merck and Novartis touting their scores at the agency. But now the FDA has delivered the coveted designation to Durham, NC-based ScioDerm, a little-known start-up that just landed its Series A of $16 million. And its success is blazing a path others can follow.
Read more: Biotech upstart joins Big Pharma cast on high-profile 'breakthrough' stage - FierceBiotech http://www.fiercebiotech.com/story/biotech-upstart-joins-big-pharma-cast-high-profile-breakthrough-stage/2013-04-30#ixzz2edV0O1dG
prr could be blockbuster from 1 october, page-8
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |